Literature DB >> 24416547

Treatment of pure uterine sarcoma at the Institut Català D'Oncologia.

Gonçalo Fernandez1, Susanna Marín I Borràs2, Valentín Navarro Pérez3, Ferran Guedea2.   

Abstract

AIM: The aim of this retrospective study was to investigate the clinical and histopathological characteristics of the disease and treatment outcome of patients with pure uterine sarcomas.
BACKGROUND: Uterine sarcomas are especially rare tumours, comprising only 3-5% of uterine cancers. They are characterized by histopathological diversity, rapid clinical progression, and poor prognosis. Optimal management consists of complete surgical removal and adjuvant radiotherapy may improve the prognosis.
MATERIALS AND METHODS: All patients with pure uterine sarcoma histology treated at our centre, the Institut Català D'Oncologia in Barcelona Spain, between 2002 and 2010 were reviewed.
RESULTS: Records of 17 patients treated at our hospital over an 8-year period were obtained. Nine patients (53%) had leiomyosarcoma, 7 (41%) had endometrial stromal sarcoma, and 1 patient had unclassified sarcoma. All patients were treated with external beam radiation after surgical excision. Mean age was 62 years (range, 51-69 years). Of the 17 patients, 13 (76%) presented with stage I disease, 2 (12%) were stage II, and 2 (12%) stage III. The overall actuarial 2-year survival estimate was 82.5%. Two patients experienced local relapse. The 2-year local control rate was 90%. A total of 5 patients experienced either local or metastatic relapse. The 2-year progression free survival rate was 58%.
CONCLUSION: In our experience, combined treatment (surgery and adjuvant radiation therapy) is effective with acceptable side effects. Larger and multicenter studies are needed to assess treatment outcome for pure uterine sarcoma histology.

Entities:  

Keywords:  Gynecology; Pure uterine sarcoma; Radiotherapy

Year:  2013        PMID: 24416547      PMCID: PMC3863295          DOI: 10.1016/j.rpor.2012.12.004

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  29 in total

Review 1.  CT and MRI of uterine sarcomas and their mimickers.

Authors:  Sung Eun Rha; Jae Young Byun; Seung Eun Jung; Soo Lim Lee; Song Mee Cho; Seong Su Hwang; Hae Giu Lee; Sung-Eun Namkoong; Jae Mun Lee
Journal:  AJR Am J Roentgenol       Date:  2003-11       Impact factor: 3.959

2.  Tamoxifen may increase risk of uterine sarcoma.

Authors:  Scott Gottlieb
Journal:  BMJ       Date:  2002-07-06

3.  Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.

Authors:  Angeles Rovirosa; Carlos Ascaso; Jaume Ordi; Rosa Abellana; Meritxell Arenas; José-Antonio Lejarcegui; Jaume Pahisa; Luis M Puig-Tintoré; Begoña Mellado; Beatríz Armenteros; Xavier Iglesias; Albert Biete
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-04-01       Impact factor: 7.038

Review 4.  Radiation therapy in the treatment of endometrial stromal sarcoma.

Authors:  H D Weitmann; T H Knocke; H Kucera; R Pötter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

Review 5.  Clinical management of uterine sarcomas.

Authors:  Frédéric Amant; An Coosemans; Maria Debiec-Rychter; Dirk Timmerman; Ignace Vergote
Journal:  Lancet Oncol       Date:  2009-12       Impact factor: 41.316

6.  The risk of developing uterine sarcoma after tamoxifen use.

Authors:  O Lavie; O Barnett-Griness; S A Narod; G Rennert
Journal:  Int J Gynecol Cancer       Date:  2008 Mar-Apr       Impact factor: 3.437

7.  Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study.

Authors:  F J Major; J A Blessing; S G Silverberg; C P Morrow; W T Creasman; J L Currie; E Yordan; M F Brady
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

8.  Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma?

Authors:  Brandon Barney; Jonathan D Tward; Thomas Skidmore; David K Gaffney
Journal:  Int J Gynecol Cancer       Date:  2009-10       Impact factor: 3.437

Review 9.  The management of patients with uterine sarcoma: a debated clinical challenge.

Authors:  Angiolo Gadducci; Stefania Cosio; Antonella Romanini; Andrea Riccardo Genazzani
Journal:  Crit Rev Oncol Hematol       Date:  2007-08-13       Impact factor: 6.312

10.  Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.

Authors:  Stefanie M Ueda; Daniel S Kapp; Michael K Cheung; Jacob Y Shin; Kathryn Osann; Amreen Husain; Nelson N Teng; Jonathan S Berek; John K Chan
Journal:  Am J Obstet Gynecol       Date:  2008-02       Impact factor: 8.661

View more
  1 in total

Review 1.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.